


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DELAY IN PUBLICATION OF AUDITED ANNUAL RESULTS FOR THE YEAR ENDED 31 MARCH 2022 AND ANNOUNCEMENT OF UNAUDITED ANNUAL RESULTS FOR THE YEAR ENDED 31 MARCH 2022

Reference is made to the announcement (the “**Announcement**”) of Innovative Pharmaceutical Biotech Limited (the “**Company**”) dated 29 June 2022 in relation to the delay in publication of audited annual results for the year ended 31 March 2022 and announcement of unaudited annual results for the year ended 31 March 2022. Unless otherwise specified used herein shall have the same meaning as those defined in the Announcement.

In relation to the Announcement, the board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to supplement that the annual report of the Company for the year ended 31 March 2022 will be dispatched to the shareholders of the Company and published on the respective websites of the Stock Exchange and the Company not later than 29 July 2022.

Save as disclosed above, the contents of the Announcement remain unchanged.

By order of the Board
Innovative Pharmaceutical Biotech Limited
Tang Rong
Executive Director

Hong Kong, 30 June 2022

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive director), Mr. Gao Yuan Xing (executive director), Mr. Tang Rong (executive director), Ms. Xiao Yan (non-executive director), Ms. Wu Yanmin (non-executive director), Ms. Chen Weijun (independent non-executive director), Mr. Chen Jinzhong (independent non-executive director) and Mr. Wang Rongliang (independent non-executive director).